Institute of Pharmacology, Centre of Biomolecular Medicine and Pharmacology, Medical University of Vienna, Austria.
EMBO Mol Med. 2010 Mar;2(3):98-110. doi: 10.1002/emmm.201000062.
Tumourigenesis caused by the Bcr/Abl oncoprotein is a multi-step process proceeding from initial to tumour-maintaining events and finally results in a complex tumour-supporting network. A key to successful cancer therapy is the identification of critical functional nodes in an oncogenic network required for disease maintenance. So far, the transcription factors Stat3 and Stat5a/b have been implicated in bcr/abl-induced initial transformation. However, to qualify as a potential drug target, a signalling pathway must be required for the maintenance of the leukaemic state. Data on the roles of Stat3 or Stat5a/b in leukaemia maintenance are elusive. Here, we show that both, Stat3 and Stat5 are necessary for initial transformation. However, Stat5- but not Stat3-deletion induces G(0)/G(1) cell cycle arrest and apoptosis of imatinib-sensitive and imatinib-resistant stable leukaemic cells in vitro. Accordingly, Stat5-abrogation led to effective elimination of myeloid and lymphoid leukaemia maintenance in vivo. Hence, we identified Stat5 as a vulnerable point in the oncogenic network downstream of Bcr/Abl representing a case of non-oncogene addiction (NOA).
Bcr/Abl 癌蛋白引起的肿瘤发生是一个多步骤的过程,从初始事件到肿瘤维持事件,最终导致一个复杂的肿瘤支持网络。成功癌症治疗的关键是鉴定致癌网络中维持疾病所需的关键功能节点。到目前为止,转录因子 Stat3 和 Stat5a/b 已被牵连到 bcr/abl 诱导的初始转化中。然而,作为一个潜在的药物靶点,信号通路必须维持白血病状态。Stat3 或 Stat5a/b 在白血病维持中的作用的数据尚不清楚。在这里,我们表明 Stat3 和 Stat5 都需要进行初始转化。然而,Stat5 的缺失而不是 Stat3 的缺失诱导伊马替尼敏感和伊马替尼耐药稳定白血病细胞的 G0/G1 细胞周期停滞和凋亡。因此,Stat5 的缺失导致体内髓系和淋巴白血病维持的有效消除。因此,我们鉴定 Stat5 为 Bcr/Abl 下游致癌网络中的一个脆弱点,代表了一种非致癌基因成瘾(NOA)的情况。